Inactive Instrument

Acura Pharmaceuticals, Inc. Stock price Nasdaq

Equities

US00509L7038

Biotechnology & Medical Research

Sales 2020 3.57M Sales 2021 1.56M Capitalization 32.54M
Net income 2020 -1M Net income 2021 - EV / Sales 2020 2.91 x
Net Debt 2020 5.86M Net Debt 2021 135K EV / Sales 2021 20.9 x
P/E ratio 2020
-5.25 x
P/E ratio 2021
-25 x
Employees -
Yield 2020 *
-
Yield 2021
-
Free-Float 15.27%
More Fundamentals * Assessed data
Dynamic Chart
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding CI
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note CI
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors CI
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets CI
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03 CI
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 CI
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC CI
Acura Pharmaceuticals, Inc. Provides Development Update on LTX-03 CI
More news
Managers TitleAgeSince
Chief Executive Officer 65 08-04-06
Director of Finance/CFO 71 98-01-31
Comptroller/Controller/Auditor 60 98-02-28
Members of the board TitleAgeSince
Director of Finance/CFO 71 98-01-31
Director/Board Member 81 98-02-28
Director/Board Member 73 96-04-30
More insiders
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
More about the company
  1. Stock
  2. Equities
  3. Stock Acura Pharmaceuticals, Inc.
  4. Stock Acura Pharmaceuticals, Inc. - Nasdaq